Syantra Files Patent for Innovative Cancer Detection Technology
The patent application addresses a pioneering method for detecting cancer signals in blood and includes associated methods of intervention.
Syantra, Inc., a privately held precision biotechnology company, has made significant strides in its mission to revolutionize cancer detection with its recent international patent filing. This application launches a transformative phase, not only focusing on early detection but also delving into methodologies that pave the way for effective treatments and interventions.
CEO Rob Lozuk expressed his enthusiasm for the patent filing, stating, "After years of research and clinical testing, I am thrilled to announce that we have filed an important patent application covering our Syantra technology platform. This marks a pivotal moment in our ongoing quest to redefine detection and treatment strategies for cancer. With advancements in our technology, Syantra is actively pursuing the global availability of this new paradigm in the fight against cancer.
The Syantra platform innovates on existing methodologies by shifting focus from traditional liquid biopsies that analyze cell-free DNA to identifying signals emitted directly from the body. This change stands to revolutionize early detection, as it can reveal the presence of cancer before it firmly establishes itself.
The core of the patent revolves around the identification of target cells in the blood that exhibit gene expression profiles linked to various cancers, particularly breast cancer. This involves creating a sophisticated integrated molecular test that leverages machine learning to improve the accuracy of early cancer diagnosis. The Syantra DX Breast Cancer Test, which is the pioneering application of this platform, has shown promising results with a remarkable sensitivity from just a 2.5 mL whole blood sample.
Additionally, COO Bob Shepherd, a founder of Syantra, elaborated on the transformative potential of their patented methodology, which not only facilitates early detection of cancer but also aids in discovering novel therapeutic pathways and drug discovery opportunities. He remarked, "This filing captures a comprehensive cycle aimed at early disease identification, providing the means for new therapeutic interventions, and effectively monitoring treatment outcomes.
Lozuk emphasized the importance of Syantra's work over the past decade, noting, "Our pioneering efforts in this patent represent a significant advancement in diagnostic and therapeutic practices, supporting a robust technological framework for future innovations." With this crucial milestone achieved, along with new funding and board members, Syantra is poised to continue its journey toward commercialization.
About Syantra
Established by a team of skilled innovators in biomedical engineering and medicine, Syantra Inc. is committed to revolutionizing how cancer is detected and treated. Supported by leading clinicians in the field, Syantra aims to change the landscape of cancer diagnostics through its cutting-edge technology. For further details, visit their official website.
Frequently Asked Questions
What is the main purpose of Syantra's recent patent filing?
The primary goal is to secure intellectual property for an innovative method of early cancer detection and associated treatment methodologies.
What distinguishes Syantra's technology from traditional cancer detection methods?
Syantra's approach focuses on signals from the body rather than solely analyzing genetic material, allowing for earlier detection of cancerous signs.
What will the Syantra DX Breast Cancer Test achieve?
It is designed to identify cancer with high sensitivity, using a minimal blood sample for reliable results.
Who are some key executives at Syantra?
Rob Lozuk serves as the CEO, while Bob Shepherd is the COO and a founder, both actively shaping the company's direction.
What are Syantra's future commercialization plans?
The company aims to commercialize its technology by 2025, as it continues to secure funding and support from new board members.
